Find Funding Opportunities

The purpose of this notice is to inform applicants of the early termination of PAR-21-059 "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)". The September 7, 2023 AIDS date has been cancelled.

Extending these NOFOs by one receipt date.

The purpose of this notice is to inform applicants of NINDS' participation in PAR-23-109 "NIH Medical Scientist Partnership Program (FM1 Clinical Trial Not Allowed)".

TheOffice of Research Quality at the National Institute of Neurological Disorders and Stroke (NINDS) is issuing this notice to inform the extramural research community about principles of rigorous biomedical research that have not yet been selected for development into educational units by previous awardees of theMaterials to Enhance Training in Experimental Rigor (METER) (UE5 Clinical Trial Not Allowed) funding opportunity. ?One receipt date remains for METER: October 10, 2023.

Adding a receipt date.

The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Biomedical Imaging and Bioengineering and participating Institutes and Centers (ICs) invite SBIR/STTR applications to develop technologies or tools to quantitatively predict or indicate an increased risk for maternal morbidity and mortality (MMM). This NOSI is part of the Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE) initiative, which supports research to reduce preventable causes of maternal deaths and improve health for women before, during, and after delivery.

The purpose of this notice is to extend PAR-20-185 "NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)" by one additional council round.

TBD

TBD

Reissue of PAR-20-122. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.